- Home
- GWH vs CTSO Comparison
GWH vs CTSO Comparison
Compare GWH & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWH
- CTSO
- Stock Information
- Founded
- GWH 2011
- CTSO 1997
- Country
- GWH United States
- CTSO United States
- Employees
- GWH N/A
- CTSO N/A
- Industry
- GWH Industrial Machinery/Components
- CTSO Medical/Dental Instruments
- Sector
- GWH Miscellaneous
- CTSO Health Care
- Exchange
- GWH Nasdaq
- CTSO Nasdaq
- Market Cap
- GWH 63.2M
- CTSO 51.6M
- IPO Year
- GWH N/A
- CTSO N/A
- Fundamental
- Price
- GWH $5.50
- CTSO $0.99
- Analyst Decision
- GWH Buy
- CTSO Strong Buy
- Analyst Count
- GWH 6
- CTSO 3
- Target Price
- GWH $2.54
- CTSO $4.67
- AVG Volume (30 Days)
- GWH 71.5K
- CTSO 497.4K
- Earning Date
- GWH 03-12-2025
- CTSO 03-06-2025
- Dividend Yield
- GWH N/A
- CTSO N/A
- EPS Growth
- GWH N/A
- CTSO N/A
- EPS
- GWH N/A
- CTSO N/A
- Revenue
- GWH $6,241,000.00
- CTSO $37,739,531.00
- Revenue This Year
- GWH $32.11
- CTSO $9.20
- Revenue Next Year
- GWH $341.09
- CTSO $11.64
- P/E Ratio
- GWH N/A
- CTSO N/A
- Revenue Growth
- GWH 31.11
- CTSO 1.80
- 52 Week Low
- GWH $4.35
- CTSO $0.70
- 52 Week High
- GWH $16.50
- CTSO $1.59
- Technical
- Relative Strength Index (RSI)
- GWH 48.82
- CTSO 49.90
- Support Level
- GWH $5.18
- CTSO $0.98
- Resistance Level
- GWH $5.82
- CTSO $1.07
- Average True Range (ATR)
- GWH 0.41
- CTSO 0.07
- MACD
- GWH 0.01
- CTSO -0.01
- Stochastic Oscillator
- GWH 50.08
- CTSO 31.53
About GWH ESS Tech Inc.
ESS Tech Inc is a long-duration energy storage company specializing in iron flow battery technology. The company design and produce long-duration batteries predominantly using earth-abundant materials.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.